Journal of Surgery Concepts & Practice >

2021 , Vol. 26 >Issue 02: 124 - 129

DOI: https://doi.org/10.16139/j.1007-9610.2021.02.008

Experts forum

Intrahepatic cholangiocarcinoma: interpretation of expert consensus and guideline from domestic and abroad

Expand

Received date: 2021-02-01

  Online published: 2022-07-27

Fold

Cite this article

WANG Chong, CHENG Shi . Intrahepatic cholangiocarcinoma: interpretation of expert consensus and guideline from domestic and abroad[J]. Journal of Surgery Concepts & Practice, 2021 , 26(02) : 124 -129 . DOI: 10.16139/j.1007-9610.2021.02.008

References

[1] Aloia T, Pawlik TM, Taouli B, et al. Cancer Staging Ma-nual[M]. 8th edition. New York: Springer, 2017:295-302.
[2] Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012[J]. Cancer, 2020, 126(11):2666-2678.
[3] Chun YS, Javle M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3):1073274817729241.
[4] Weber SM, Ribero D, O′Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement[J]. HPB (Oxford), 2015, 17(8):669-680.
[5] 国际肝胆胰学会中国分会, 中华医学会外科学分会肝脏外科学组. 胆管癌诊断与治疗—外科专家共识[J]. 临床肝胆病杂志, 2015(1):12-16.
[6] 胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24(9):828-838.
[7] National Comprehensive Cancer Network. Hepatobiliary Cancers, Version 5[J/OL]. 2020-08-04. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
[8] 科技部传染病防治重大专项课题“病毒性肝炎相关肝癌外科综合治疗的个体化和新策略”专家组. 肝内胆管癌外科治疗中国专家共识(2020版)[J]. 中华消化外科杂志, 2021, 20(1):1-15.
[9] Goere D, Wagholikar GD, Pessaux P, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma[J]. Surg Endosc, 2006, 20(5):721-725.
[10] Nakanuma Y, Curado MP, Franceschi S, et al. Intrahe-patic cholangiocarcinoma[M]. 4th edition.Lyon: IARC Press, 2010:217-222.
[11] Liau JY, Tsai JH, Yuan RH, et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiolo-gical, clinicopathological, and molecular features[J]. Mod Pathol, 2014, 27(8):1163-1173.
[12] Krasinskas AM. Cholangiocarcinoma[J]. Surg Pathol Clin, 2018, 11(2):403-429.
[13] Spolverato G, Bagante F, Weiss M, et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2017, 115(6):696-703.
[14] Kang SH, Hwang S, Lee YJ, et al. Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2018, 25(4):240-248.
[15] Yamamoto Y, Sugiura T, Okamura Y, et al. The evaluation of the eighth edition of the AJCC/UICC staging system for intrahepatic cholangiocarcinoma: a proposal of a modified new staging system[J]. J Gastrointest Surg, 2020, 24(4):786-795.
[16] Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol, 2013, 31(9):1188-1195.
[17] 董家鸿, 郑树森, 陈孝平, 等. 肝切除术前肝脏储备功能评估的专家共识(2011版)[J]. 中华消化外科杂志, 2011, 10(1):20-25.
[18] 中华医学会数字医学分会, 中国医师协会肝癌专业委员会, 中国医师协会精准医学专业委员会, 等. 原发性肝癌三维可视化技术操作及诊疗规范(2020版)[J]. 中国实用外科杂志, 2020, 40(9):991-1011.
[19] Spolverato G, Yakoob MY, Kim Y, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(12):4020-4028.
[20] Yoh T, Cauchy F, Le Roy B, et al. Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: a multicenter study[J]. Surgery, 2019, 166(6):975-982.
[21] 程石, 王冲. 肝内胆管细胞癌的外科治疗策略[J]. 国际外科学杂志, 2020, 47(6):365-368.
[22] Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4):1178-1188.
[23] Rana A, Hong JC. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2012, 28(3):258-265.
[24] Sahai P, Kumar S. External radiotherapy and brachythe-rapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence[J]. Br J Radiol, 2017, 90(1076):20170061.
[25] Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer[J]. Br J Surg, 2018, 105(3):192-202.
[26] Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673.
[27] Mizusawa J, Morizane C, Okusaka T, et al. Randomized Phase Ⅲ study of gemcitabine plus S-1 versus gem-citabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study(JCOG1113, FUGA-BT)[J]. Jpn J Clin Oncol, 2016, 46(4):385-388.
[28] Phelip JM, Vendrely V, Rostain F, et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phaseⅡ randomised study[J]. Eur J Cancer, 2014, 50(17):2975-2982.
[29] Jackson MW, Amini A, Jones BL, et al. Treatment selection and survival outcomes with and without radiation for unresectable, localized intrahepatic cholangiocarcinoma[J]. Cancer J, 2016, 22(4):237-242.
[30] Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26):2509-2520.
[31] Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metasta-tic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5):671-684.
[32] Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2015, 111(2):213-220.
[33] Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J]. Ann Surg Oncol, 2016, 23(1):235-243.
Options
Outlines

/

〈 〉